{
    "2020-02-19": [
        [
            {
                "time": "",
                "original_text": "斥资3000万美元进军罕见病领域，药明康德拟打造医药界的“阿里系”？",
                "features": {
                    "keywords": [
                        "药明康德",
                        "罕见病",
                        "3000万美元",
                        "阿里系"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "北海康成完成9800万美元D轮融资，领投方为泛大西洋投资集团和药明康德",
                "features": {
                    "keywords": [
                        "北海康成",
                        "9800万美元",
                        "D轮融资",
                        "药明康德",
                        "泛大西洋投资集团"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "速递 | 癌症早期血检结果有望影响治疗选择，GRAIL启动首个干预性临床试验",
                "features": {
                    "keywords": [
                        "癌症",
                        "早期血检",
                        "GRAIL",
                        "干预性临床试验"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德背后的“资本大拿”李革",
                "features": {
                    "keywords": [
                        "药明康德",
                        "李革",
                        "资本大拿"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}